Immunosuppression in the pediatric transplant recipient

Area of Science:

• Pediatric transplantation
• Immunosuppression management
• Organ transplant outcomes

Background:

• Pediatric solid-organ transplantation has evolved significantly, becoming more routine globally.
• Care for pediatric recipients is complex, differing from adults mainly in immunosuppression management.
• Calcineurin inhibitors (tacrolimus, cyclosporine) are central to post-transplant immunosuppression but carry risks.

Purpose of the Study:

• To review the evolution and current state of pediatric solid-organ transplantation.
• To highlight the complexities of immunosuppression in pediatric recipients.
• To discuss the long-term goals of minimizing immunosuppression and achieving graft tolerance.

Main Methods:

• Review of advancements in surgical techniques and medication regimens.
• Analysis of current immunosuppression strategies in pediatric solid-organ transplantation.
• Discussion of long-term side effects and management goals.

Main Results:

• Transplantation is now a routine procedure with increasing recipient numbers worldwide.
• Calcineurin inhibitors are standard but associated with nephrotoxicity and neurotoxicity.
• Significant variation exists in pediatric immunosuppression regimens globally.

Conclusions:

• Minimizing immunosuppression exposure is crucial for long-term pediatric transplant survivors.
• Achieving long-term graft tolerance is the primary goal in managing pediatric organ recipients.
• Addressing the long-term side effects of immunosuppression is key to improving outcomes.